Correction, 18 September 2026: an earlier version of this post described April 23 as the end of the quarter. It is the date the results were reported.
What changed
WST (West Pharmaceutical Services) reported results on April 23, 2026. EPS came in at $2.13, up from $1.45 in the same period a year earlier — a year-over-year increase of 46.9%. Revenue grew 21.0% year over year. Both figures represent a meaningful acceleration in the business.
The stock trades at $359.05 with a market cap of $25.38B. The trailing P/E stands at 47.1 and the forward P/E at 41.0, reflecting a market that is pricing in continued earnings growth. We do not have guidance commentary from management to share at this time.
Recevez le résumé hebdomadaire ACCE
Performance des indices, bilan des sélections, plus fortes variations de score : chaque dimanche, sans superflu.
What it means
The ACCE score for WST is 73/100. The breakdown tells a clear story: Momentum leads at 97, Growth sits at 88, and Quality comes in at 80. Value is the outlier at 25, which lines up with the premium multiple the stock carries.
On quality metrics, WST posts a net margin of 16.9% and ROE of 19.1%. Those are strong numbers for a healthcare components manufacturer. FCF yield is 1.9%, and the platform carries an "earnings quality: strong" tag in our model.
The 1-year return is 64.0%, which helps explain the momentum score. The stock has moved sharply, and the valuation reflects that. Our 6-model fair value estimate sits at $156.69, which is 56.4% below the current price of $359.05. That gap is wide. It does not mean the stock falls tomorrow, but it does mean the current price requires the earnings trajectory to hold — or improve.
The analyst consensus target is $382.00, implying modest upside from current levels. The dividend yield is 0.2%, so this is not an income story.
The quarter reported on April 23, 2026 showed WST executing well. Revenue and earnings both grew at double-digit rates, and the quality metrics back up the headline numbers. The question the valuation raises is how much of that execution is already in the price. With a Value score of 25 and a 6-model fair value well below the current price, buyers here are paying for a lot of future growth to materialize.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
